ACET

Adicet Bio, Inc. NASDAQ

Healthcare ·Biotechnology ·US · adicetbio.com

$8.45

Mkt Cap $81.1M

52w Low $6.01 21.3% of range 52w High $17.44

50d MA $7.29 200d MA $9.78

P/E (TTM) -0.5x

EV/EBITDA -0.3x

P/B 0.3x

Debt/Equity 0.1x

ROE -73.4%

P/FCF -0.6x

RSI (14) —

ATR (14) —

Beta 1.58

50d MA $7.29

200d MA $9.78

Avg Volume 149.9K

About

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-3.23	-2.94	+9.0%	7.04	-0.9%	+2.4%	+1.8%	+2.1%	-1.6%	+0.4%	—
Nov 5, 2025	AMC	-4.16	-4.64	-11.5%	11.04	+0.0%	-1.9%	-7.3%	-4.8%	-6.3%	-0.5%	—
Aug 7, 2025	AMC	-5.12	-5.44	-6.2%	10.99	-1.0%	-9.6%	-13.2%	-7.0%	-0.1%	-5.4%	—
May 6, 2025	AMC	-5.44	-4.96	+8.8%	9.64	-0.4%	-18.6%	-20.6%	+1.2%	+19.7%	+10.9%	—
Mar 6, 2025	AMC	-5.92	-5.12	+13.5%	13.54	-3.1%	-5.9%	-9.8%	-6.8%	-6.2%	-8.3%	—
Nov 6, 2024	AMC	-5.76	-5.44	+5.6%	20.80	+0.0%	+2.3%	+0.8%	-3.1%	-7.7%	-12.3%	—
Aug 13, 2024	AMC	-5.60	-5.28	+5.7%	20.80	+1.5%	+5.4%	+10.0%	+17.7%	+19.2%	+13.1%	—
May 14, 2024	AMC	-5.60	-5.60	+0.0%	21.28	+6.0%	+5.3%	+18.0%	+20.3%	+21.8%	+21.1%	—
Mar 19, 2024	AMC	-11.52	-11.04	+4.2%	32.48	+9.4%	+5.4%	+0.5%	+7.9%	+8.4%	+10.3%	—
Nov 8, 2023	AMC	-11.68	-11.36	+2.7%	21.28	-2.3%	-6.0%	-9.8%	-11.3%	-11.3%	-9.0%	—
Aug 9, 2023	AMC	-10.88	-12.00	-10.3%	33.60	-4.3%	+11.9%	+9.5%	+1.9%	+1.4%	-1.9%	—
May 9, 2023	AMC	-11.84	-11.52	+2.7%	107.68	+3.4%	+3.0%	-1.0%	-5.5%	+5.9%	+1.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 5	Jefferies	Reiterates	Buy	$19	—	—	—	—	—	—	—	—
Mar 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.92	$6.82	-1.4%	-3.8%	-3.3%	-1.6%	-2.7%	-6.5%
Mar 13	Guggenheim	Maintains	Buy → Buy	—	$7.04	$6.98	-0.9%	+2.4%	+1.8%	+2.1%	-1.6%	+0.4%
Jan 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.90	$8.13	+2.9%	+2.2%	+6.3%	+6.8%	+10.1%	+8.1%
Jan 6	Canaccord Genuity	Maintains	Buy → Buy	—	$8.15	$8.10	-0.6%	-1.2%	+3.7%	-0.7%	-1.5%	-4.2%
Nov 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.83	$10.72	-1.0%	-5.5%	-3.0%	-4.5%	+1.4%	-2.0%
Oct 8	Guggenheim	Maintains	Buy → Buy	—	$13.65	$13.76	+0.8%	+8.9%	+7.2%	+13.4%	+14.8%	+12.5%
Sep 19	Guggenheim	Maintains	Buy → Buy	—	$12.97	$13.12	+1.2%	-1.9%	+1.2%	+2.4%	+5.5%	+3.5%
Mar 21	Guggenheim	Maintains	Buy → Buy	—	$12.23	$12.23	+0.0%	+0.2%	+19.6%	+15.8%	+17.3%	+11.2%
Mar 7	Citizens Capital Markets	Maintains	Market Perform → Market Perform	—	$13.54	$13.12	-3.1%	-5.9%	-9.8%	-6.8%	-6.2%	-8.3%
Mar 7	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$13.54	$13.12	-3.1%	-5.9%	-9.8%	-6.8%	-6.2%	-8.3%
Feb 27	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$14.44	$14.76	+2.2%	-4.8%	-0.4%	-6.1%	-3.5%	-3.0%
Feb 6	JMP Securities	Maintains	Market Perform → Market Perform	—	$16.16	$15.68	-3.0%	+2.0%	-4.5%	-10.9%	-10.8%	-14.2%
Feb 5	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$14.72	$15.97	+8.5%	+9.8%	+12.0%	+4.9%	-2.2%	-2.0%
Dec 19	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$14.33	$14.72	+2.7%	-4.0%	+1.6%	-0.2%	+2.3%	+7.2%
Aug 14	Canaccord Genuity	Maintains	Buy → Buy	—	$20.80	$21.12	+1.5%	+5.4%	+10.0%	+17.7%	+19.2%	+13.1%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.80	$21.12	+1.5%	+5.4%	+10.0%	+17.7%	+19.2%	+13.1%
Jul 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.12	$19.20	+12.1%	+9.3%	+13.1%	+18.7%	+17.8%	+13.1%
Jun 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.92	$22.40	+2.2%	+9.5%	+7.3%	-2.2%	-2.2%	-11.7%
Jun 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.76	$22.88	+5.1%	+5.9%	+2.9%	-0.7%	-3.7%	-5.1%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.28	$22.56	+6.0%	+5.3%	+18.0%	+20.3%	+21.8%	+21.1%
Apr 23	Wedbush	Maintains	Outperform → Outperform	—	$32.00	$34.24	+7.0%	+5.0%	-6.0%	-9.5%	-16.0%	-20.5%
Apr 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.40	$37.60	-2.1%	-1.7%	-5.8%	-5.0%	-6.2%	-9.2%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.48	$35.52	+9.4%	+5.4%	+0.5%	+7.9%	+8.4%	+10.3%
Mar 20	Canaccord Genuity	Maintains	Buy → Buy	—	$32.48	$35.52	+9.4%	+5.4%	+0.5%	+7.9%	+8.4%	+10.3%
Mar 20	Wedbush	Maintains	Outperform → Outperform	—	$32.48	$35.52	+9.4%	+5.4%	+0.5%	+7.9%	+8.4%	+10.3%
Feb 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$49.44	$48.80	-1.3%	-2.9%	+1.0%	+3.2%	+3.9%	+9.4%
Jan 5	Canaccord Genuity	Maintains	Buy → Buy	—	$34.56	$33.76	-2.3%	+12.0%	+13.9%	+59.7%	+55.1%	+40.7%
Nov 9	Wedbush	Maintains	Outperform → Outperform	—	$21.28	$20.80	-2.3%	-6.0%	-9.8%	-11.3%	-11.3%	-9.0%
Sep 6	Truist	Maintains	Buy → Buy	—	$29.76	$29.44	-1.1%	-2.7%	-4.3%	-9.1%	-8.6%	-14.0%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.60	$36.80	-2.1%	-2.1%	-8.9%	-9.4%	-12.3%	-16.2%
Aug 10	Wedbush	Maintains	Outperform → Outperform	—	$33.60	$32.16	-4.3%	+11.9%	+9.5%	+1.9%	+1.4%	-1.9%
Aug 10	BTIG	Maintains	Buy → Buy	—	$33.60	$32.16	-4.3%	+11.9%	+9.5%	+1.9%	+1.4%	-1.9%
Jun 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$74.56	$61.44	-17.6%	-54.3%	-43.3%	-50.4%	-47.9%	-41.4%
Jun 27	Guggenheim	Downgrade	Buy → Neutral	—	$74.56	$61.44	-17.6%	-54.3%	-43.3%	-50.4%	-47.9%	-41.4%
Jun 27	JMP Securities	Downgrade	Market Outperform → Market Perform	—	$74.56	$61.44	-17.6%	-54.3%	-43.3%	-50.4%	-47.9%	-41.4%
Jun 1	JP Morgan	Downgrade	Overweight → Neutral	—	$87.68	$81.60	-6.9%	-5.1%	-2.4%	-4.0%	-2.9%	+4.2%
May 15	JMP Securities	Maintains	Market Outperform → Outperform	—	$101.76	$102.40	+0.6%	+12.1%	+7.4%	+4.9%	+1.6%	-1.3%
May 15	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$101.76	$102.40	+0.6%	+12.1%	+7.4%	+4.9%	+1.6%	-1.3%
May 10	Wedbush	Maintains	Outperform → Outperform	—	$107.68	$111.36	+3.4%	+3.0%	-1.0%	-5.5%	+5.9%	+1.5%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$107.68	$111.36	+3.4%	+3.0%	-1.0%	-5.5%	+5.9%	+1.5%
Mar 16	Wedbush	Maintains	Outperform → Outperform	—	$123.36	$118.88	-3.6%	+0.0%	-3.6%	-16.9%	-14.8%	-22.4%
Mar 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$123.36	$118.88	-3.6%	+0.0%	-3.6%	-16.9%	-14.8%	-22.4%
Dec 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$276.32	$173.60	-37.2%	-39.6%	-37.5%	-38.4%	-42.4%	-45.6%
Sep 21	JP Morgan	Maintains	Overweight → Overweight	—	$236.96	$244.64	+3.2%	-3.5%	-7.8%	-6.1%	-6.9%	-7.2%
Mar 31	SMBC Nikko	Maintains	Outperform → Outperform	—	$313.12	$314.24	+0.4%	+2.0%	+6.3%	+1.2%	-1.8%	-1.0%
Mar 17	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$255.04	$249.76	-2.1%	+1.9%	+1.0%	-5.1%	+5.1%	+3.9%
Mar 8	Truist	Maintains	Buy → Buy	—	$200.96	$207.52	+3.3%	+4.1%	+14.0%	+12.3%	+4.4%	-2.1%
Mar 4	Jefferies	Maintains	Buy → Buy	—	$196.96	$201.60	+2.4%	+2.0%	+2.0%	+6.2%	+16.3%	+14.6%
Dec 6	Guggenheim	Maintains	Buy → Buy	—	$156.80	$218.40	+39.3%	+38.5%	+47.9%	+56.0%	+40.2%	+41.7%

Recent Filings

8-K

Unknown — 8-K Filing

Adicet's strong Phase 1 enrollment and positive autoimmune therapy data suggest clinical progress that could accelerate pipeline advancement and reduce development risk, making the stock attractive for investors betting on gamma delta T-cell therapy success.

Mar 12

Data updated apr 24, 2026 10:28am · Source: massive.com